LUND, Sweden, Oct. 31, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) announces today that the subscription period for the warrants of series 2018:1, issued in connection with the Company's rights issue which...
from PR Newswire: //https://ift.tt/2PtAjd2
No comments:
Post a Comment